Liquid-phase synthesis method of eptifibatide

Abstract

The invention relates to a liquid phase synthesis method of eptifibatide. The liquid phase synthesis method comprises six stages of synthesizing tripeptide, synthesizing tetrapeptide, cyclizing, removing a protecting group and guanidinylating. The liquid phase synthesis method of the eptifibatide, provided by the invention, solves the problem of generation of by-products in a process of synthesizing a intramolecular disulfide bond to cyclic peptide, relative conditions of removal of a cyclic peptide side chain protecting group are established, conditions and a method of converting cyclic peptide amino to guanidyl are established, and the yield is improved; furthermore, raw material reagents used in the method are cheap and easy to obtain, the product cost is effectively reduced, and the production benefit is remarkably improved.

Description

technical field [0001] The invention relates to a liquid-phase synthesis method of eptifibatide, which belongs to the field of biochemistry. Background technique [0002] Eptifibatide was developed by COR Therapeutic Company of the United States and launched in the United States in 1998 for the treatment of acute coronary syndrome. By inhibiting coagulation factor I, it binds to platelet glycoprotein IIb / IIIa receptors, thereby inhibiting platelet aggregation. In clinical application, it has shown good curative effect on the treatment of cardiovascular diseases such as unstable angina, acute myocardial infarction, and coronary intervention. At present, cardiovascular diseases are increasing year by year and have become one of the common diseases that pose a serious threat to human health in modern society. As a polypeptide cardiovascular system drug, eptifibatide has the advantages of high efficacy and low side effects, and has been widely used in clinical practice. applic...

AI Technical Summary

Problems solved by technology

Although this method can effectively synthesize eptifibatide, the raw materials are expensive, and there are many by-products in the synthesis of linear peptides, and the utilization rate of raw materials is low

[0004] The existing liquid phase synthesis method is also reported. Patent CN200,910,101,674 discloses a new full liquid phase synthesis method of eptifibatide, and patent CN200,910,156,804 provides a synthetic liquid phase preparation process of eptifibatide. But the yield of eptifibatide in these liquid phase synthesis methods is low, is not suitable for industrialized production

[0005] Among the currently known synthetic methods, the solid-phase synthesis of eptifibatide is an ideal method for laboratory research. This method is efficient and rapid, but the raw material utilization rate of the solid-phase synthesis method is low, and the reagents and solvents used are expensive. And it is not easy to handle, commonly used solvents such as ethanedithiol and DMF are highly toxic and not suitable for industrial production

In addition, this method uses expensive homoarginine as a starting material, which has poor solubility in organic solvents, resulting in increased by-products and reduced synthesis efficiency.

In addition, in the existing liquid-phase synthesis method, due to the low yield, only small-scale production can only be carried out in a reactor of about 1L

These all lead to the increase of the patient's burden due to the high price of eptifibatide. Therefore, there is an urgent need for a new synthetic method that can be produced on a large scale to reduce the cost of eptifibatide and reduce the price of eptifibatide. , to reduce the financial burden on patients

Images